<DOC>
	<DOCNO>NCT01305226</DOCNO>
	<brief_summary>This novel fibrinolytic agent 136 amino acid single chain protein secrete strain Staphylococcus aureus readily produce recombinant DNA technology . Two natural variant recombinant staphylokinase , THR-100 SakSTAR , develop investigational use preliminary trial . Like SK , form equimolar complex plasmin turn activate plasminogen plasmin . Unlike SK , complexed , activate molecule ( undergoes proteolytic cleavage first ten amino acid generate active staphylokinase ) high degree fibrin-selectivity human plasma milieu . This fibrin-selectivity due large measure potent activation clot surface trace amount plasmin , rapid inactivation circulate complex antiplasmin . Hence , provide interesting promise alternative therapy .</brief_summary>
	<brief_title>A Trial Using Double-Bolus THR-100 Versus Streptokinase</brief_title>
	<detailed_description>STUDY SUMMARY/PROTOCOL OUTLINE Protocol Number : BBIL/STA/O5/2007 Protocol Name : A PROSPECTIVE PHASE III PARALLEL , RANDOMISED CONTROLLED TRIAL USING DOUBLE-BOLUS THR-100 ( RECOMBINANT STAPHYLOKINASE ) Vs STREPTOKINASE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION Drug Study : THR-100 ( Recombinant Staphylokinase ) Intended Indication : Acute Myocardial Infarction Study Design : Randomized , Parallel Group , Multicenter Active-Comparator Trial . Patient Population : Patients age 30 ≤ 75 year present acute myocardial infarction within 12 hour onset symptom presume secondary acute myocardial infarction . Number Patients : 120 subject recruit trial , patient randomize 1:1 allocation ratio THR-100 Streptokinase three center . This sample size 120 subject provide power 0.90 significance level 0.05 yield statistically significant early patency difference . Primary Objectives : To demonstrate efficacy THR100 compare streptokinase assessment 12-lead Electrocardiogram , specific cardiac Enzymes level , pain relief TIMI-90 . ( Non-Inferiority study ) Secondary Objectives : To evaluate safety profile recombinant SAK comparison Streptokinase . Dose Levels : Dose level ( administer intravenously ) . THR-100 : 15 mg double-bolus ( 15mg/15ml ) , separate 30 minute ( total 30 mg ) Streptokinase : Standard regimen ( 1.5 million IU ) make 150 ml physiological saline glucose solution administer intravenously period 60 minute . Study Parameters : Primary endpoint : 1 . 12-lead Electrocardiogram , ≥50 % resolution ST segment single ECG lead maximum deviation present 90 minute 24 hour start thrombolytic therapy . 2 . Changes cardiac Enzyme level CK-MB Cardiac Troponin I T 6 hr , 8 hr , 12-16 hr 24 hour start thrombolytic therapy . 3 . Significant Relief pain ( 3 point reduction 0-5 subjective scale ) end 2 12 hrs start thrombolytic therapy . ( 0-No pain , 1-Slight pain , 2-Mild pain , 3-Moderate pain , 4- Severe pain , 5-Very severe pain ) . 4 . Assessment culprit coronary vessel patency ( TIMI- grade 3 ) 90 minute . ( TIMI- Thrombolysis myocardial infarction ) . Angiography shall perform patient fulfil follow guideline 1 . No WPW LBBB IV-conduction block Pacemaker rhythm . 2 . ≥0.2 mV ST elevation ≥2 lead V1-V6 ≥0.3 mV ST elevation ≥1 lead V1-V6 3 . Sum ST elevation V1-V6 plus Sum ST depression II , III , aVF ≥0.8 mV ( OR ) 1 . No WPW LBBB IV-conduction block Pacemaker rhythm . 2 . ≥0.1 mV ST elevation ≥2 lead II , III , aVF ≥0.2 mV ST elevation ≥1 lead II , III , aVF 5 ) . Sum ST elevation I-III , aVF plus Sum ST depression V1-V4 ≥0.6 mV . Secondary endpoint : Assessment net clinical benefit , define reduced mortality , non-fatal stroke , clinically-evident intracranial hemorrhage , recurrent myocardial infarction thirty ( 30 ) day . Assessment rate follow in-hospital event define Appendix 1 : - Heart failure , - In-hospital death , - Recurrent myocardial infarction , - Refractory ischemia , - need urgent revascularization , - Major complication ( cardiogenic shock , major arrhythmia , pericarditis , tamponade , acute hemodynamically severe mitral regurgitation , acute ventricular septal defect ) , Safety consideration : - Stroke , - Intracranial hemorrhage ( see stroke ) , - Major bleeding ( intracranial hemorrhage ) , - Bleeding major , - Serious non-serious adverse event ( see Section 14 ) , - Allergic reaction , - Laboratory data . Other angiographic end point CTFC ( Corrected TIMI Frame Count ) , Angiography perform .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Streptokinase</mesh_term>
	<criteria>1 . Male female patient age 30 &lt; 75 year inclusive . 2 . Patients present within 12 hour symptom presume secondary acute myocardial infarction last least 20 minute accompany ECG evidence &gt; 1mm ST elevation 2 limb lead &gt; 2mm 2 contiguous precordial lead suspect new left bundle branch block eligible . 3 . Patients must hospital emergency department able receive study medication within 12 hour onset symptom . 4 . Females childbearing age , use generally accept method contraception must negative urine pregnancy test . 5 . Written inform consent sought patient prior inclusion study . If unable , informed verbal consent obtain . If neither possible , legally acceptable representative ( relative ) provide write consent . 6 . NB Verbal write consent follow write informed consent patient early subsequent opportunity . 1 . Previous administration staphylokinase . 2 . Active bleed know hemorrhagic diathesis . 3 . Any history stroke , transient ischemic attack , dementia , structural CNS damage e.g . neoplasm , aneurysm , AV malformation . 4 . Major surgery trauma within past 3 month . 5 . Significant hypertension i.e . SBP 180 mm Hg and/or DBP 110 mm Hg time admission randomization . 6 . Current treatment vitamin K antagonists result INR &gt; 1.5 . 7 . Anticipated difficulty vascular access . 8 . Prolonged ( &gt; 10 min ) cardiopulmonary resuscitation cardiogenic shock . 9 . Patients participate investigational drug study within past 30 day . 10 . Pregnancy lactation , parturition within previous 30 day . 11 . Any serious concomitant systemic life limit disorder would incompatible trial 12 . Patients know history life limit malignant disease HIV . 13 . Significant hepatic renal dysfunction condition , opinion Investigator , make patient unsuitable study entry . 14 . Previous participation trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>THR 100</keyword>
</DOC>